eligibility_summary
Adults ≥18 with recurrent/relapsed advanced ovarian, primary peritoneal, fallopian tube, cholangiocarcinoma, or epithelial mesothelioma (pleural/peritoneal) after ≥1 prior systemic therapy, ECOG 0–1, measurable disease (iRECIST/mRECIST), adequate coagulation, organ and marrow. Excludes other active cancers (unless cured ≥5y), T/B‑cell malignancies or prior engineered T cells, sarcomatoid/biphasic mesothelioma, pulmonary issues, immunodeficiency, active HBV/HCV/HIV, or autoimmune disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
SynKIR-110 is an autologous gene-modified cellular therapy: patient T cells engineered to express a mesothelin-directed KIR-CAR (killer immunoglobulin–like receptor chimeric antigen receptor). Type: biological, CAR T-cell therapy. Given as a single IV infusion after lymphodepleting chemotherapy in a Phase 1 dose-escalation study. Mechanism of action: the KIR-CAR binds mesothelin on tumor cells, triggering KIR-based activation signaling within the engineered T cell to drive cytotoxic killing and cytokine release. Targets: mesothelin-expressing malignant cells in ovarian cancer, cholangiocarcinoma, and mesothelioma. Pathways/cells engaged: mesothelin antigen on tumor cells, activated T-cell effector pathways (e.g., antigen-specific recognition and cytotoxicity). Primary aims: safety, feasibility, and preliminary antitumor activity.